Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy (Q40430867)

20 September 2017

Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy (English)

1 reference

20 September 2017

1 reference

Salmonella choleraesuis

object named as

Salmonella choleraesuis

1 reference

Che-Hsin Lee

1

1 reference

20 September 2017

Chao-Liang Wu

series ordinal

2

1 reference

20 September 2017

Yun-Sheng Tai

series ordinal

3

1 reference

20 September 2017

Ai-Li Shiau

series ordinal

4

1 reference

20 September 2017

1 May 2005

1 reference

20 September 2017

1 reference

20 September 2017

11

1 reference

20 September 2017

5

1 reference

20 September 2017

707-716

1 reference

Bacteria as tumour-targeting vectors

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Prothymosin alpha enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

THE IMMUNIZATION OF MICE, CALVES AND PIGS AGAINST SALMONELLA DUBLIN AND SALMONELLA CHOLERAE-SUIS INFECTIONS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Antitumor Activity of Polymorphonuclear Leukocytes Activated by a .BETA.-1,3-D-Glucan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: implication of monocyte-derived neutrophil-activating factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

Combination bacteriolytic therapy for the treatment of experimental tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.008

10.1016/J.YMTHE.2005.01.008

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference